A vital role for complement in heart disease

Molecular Immunology

Volumn 61, Issue 2, 2014, Pages 126-134

  Lappegård, Knut T ^a,b   Garred, Peter ^c   Jonasson, Lena ^d   Espevik, Terje ^e   Aukrust, Pål ^f,g   Yndestad, Arne ^f,g   Mollnes, Tom E ^a,b,e,f,g   Hovland, Anders ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c Rigshospitalet   (Denmark)

^d LINKÖPING UNIVERSITY   (Sweden)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

Atrial fibrillation; Chagas disease; Complement system; Coronary heart disease; Heart failure; Myocardial infarction

Indexed keywords

COMPLEMENT; PEXELIZUMAB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHAGAS DISEASE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; RISK FACTOR;

PROTOZOA;

ATRIAL FIBRILLATION; CHAGAS DISEASE; COMPLEMENT SYSTEM; CORONARY HEART DISEASE; HEART FAILURE; MYOCARDIAL INFARCTION;

ANIMALS; COMPLEMENT SYSTEM PROTEINS; HEART DISEASES; HUMANS;

EID: 84907597158     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.06.036     Document Type: Review

References (118)

1. Adamsson Eryd S., Smith J.G., Melander O., Hedblad B., Engström G. Inflammation-sensitive proteins and risk of atrial fibrillation: a population-based cohort study. Eur. J. Epidemiol. 2011, 26:449-455.
2. Aiello V.D., Reis M.M., Benvenuti L.A., Higuchi M., Ramires d.L.J.A., Halperin J.A. A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy. J. Pathol. 2002, 197:224-229.
3. Alipour A., Cabezas M.C., Elte J.W., Vallvé J.C., Ribalta J., Zwinderman A.H., Defesche J.C., Jukema J.W. Mannose binding lectin 2 haplotypes do not affect the progression of coronary atherosclerosis in men with proven coronary artery disease treated with pravastatin. Atherosclerosis 2011, 215:125-129.
4. APEX AMI Investigators Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. J. Am. Med. Assoc. 2007, 297:43-51.
5. Atefi G., Zetoune F.S., Herron T.J., Jalife J., Bosmann M., Al-Aref R., Sarma J.V., Ward P.A. Complement dependency of cardiomyocyte release of mediators during sepsis. Fed. Am. Soc. Exp. Biol. J. 2011, 25:2500-2508.
6. Aukrust P., Gullestad L., Lappegard K.T., Ueland T., Aass H., Wikeby L., Simonsen S., Froland S.S., Mollnes T.E. Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation 2001, 104:1494-1500.
7. Banz Y., Rieben R. Role of complement and perspectives for intervention in ischemia-reperfusion damage. Ann. Med. 2012, 44:205-217.
8. Barratt-Due A., Pischke S.E., Brekke O.L., Thorgersen E.B., Nielsen E.W., Espevik T., Huber-Lang M., Mollnes T.E. Bride and groom in systemic inflammation - the bells ring for complement and Toll in cooperation. Immunobiology 2012, 217:1047-1056.
9. Beucher M., Norris K.A. Sequence diversity of the Trypanosoma cruzi complement regulatory protein family. Infect. Immun. 2008, 76:750-758.
10. Bjerre M., Kistorp C., Hansen T.K., Faber J., Lip G.Y., Hildebrandt P., Flyvbjerg A. Complement activation, endothelial dysfunction, insulin resistance and chronic heart failure. Scand. Cardiovasc. J. 2010, 44:260-266.
11. Blaskó B., Kolka R., Thorbjornsdottir P., Sigurdarson S.T., Sigurdsson G., Rónai Z., Sasvári-Székely M., Bödvarsson S., Thorgeirsson G., Prohászka Z., Kovács M., Füst G., Arason G.J. Low complement C4B gene copy number predicts short-term mortality after acute myocardial infarction. Int. Immunol. 2008, 20:31-37.
12. Bocchi E.A., Arias A., Verdejo H., Diez M., Gómez E., Castro P. The reality of heart failure in Latin America. J. Am. Coll. Cardiol. 2013, 62:949-958. Interamerican Society of Cardiology.
13. Bruins P., te Velthuis H., Yazdanbakhsh A.P., Jansen P.G., van Hardevelt F.W., de Beaumont E.M., Wildevuur C.R., Eijsman L., Trouwborst A., Hack C.E. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997, 96:3542-3548.
14. Busche M.N., Pavlov V., Takahashi K., Stahl G.L. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1853-H1859.
15. Cestari I., Evans-Osses I., Freitas J.C., Inal J.M., Ramirez M.I. Complement C2 receptor inhibitor trispanning confers an increased ability to resist complement-mediated lysis in Trypanosoma cruzi. J. Infect. Dis. 2008, 198:1276-1283.
16. Cestari I., Krarup A., Sim R.B., Inal J.M., Ramirez M.I. Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi. Mol. Immunol. 2009, 47:426-437.
17. Cestari I., Ansa-Addo E., Deolindo P., Inal J.M., Ramirez M.I. Trypanosoma cruzi immune evasion mediated by host cell-derived microvesicles. J. Immunol. 2012, 188:1942-1952.
18. Chan M.Y., Lin M., Lucas J., Moseley A., Thompson J.W., Cyr D., Ueda H., Kajikawa M., Ortel T.L., Becker R.C. Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thromb. Haemost. 2012, 108:1180-1191.
19. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., Gillum R.F., Kim Y.H., McAnulty J.H., Zheng Z.J., Forouzanfar M.H., Naghavi M., Mensah G.A., Ezzati M., Murray C.J. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014, 129:837-847.
20. Cook C., Cole G., Asaria P., Jabbour R., Francis D.P. The annual global economic burden of heart failure. Int. J. Cardiol. 2014, 171:368-376.
21. Cubedo J., Padró T., Badimon L. Coordinated proteomic signature changes in immune response and complement proteins in acute myocardial infarction: the implication of serum amyloid P-component. Int. J. Cardiol. 2013, 168:5196-5204.
22. del Balzo U.H., Levi R., Polley M.J. Cardiac dysfunction caused by purified human C3a anaphylatoxin. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:886-890.
23. Dernellis J., Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am. J. Cardiol. 2006, 97:245-248.
24. Di Domeinco M., Scumaci D., Grasso S., Gaspari M., Curcio A., Oliva A., Ausania F., Di Nunzio C., Ricciardi C., Santini A.C., Rizzo F.A., Romano Carratelli C., Lamberti M., Conti D., La Montagna R., Tomei V., Malafoglia V., Pascali V.L., Ricci P., Indolfi C., Costanzo F., Cuda G. Biomarker discovery by plasma proteomics in familial Brugada syndrome. Front. Biosci. (Landmark Ed.) 2013, 18:564-571.
25. Distelmaier K., Adlbrecht C., Jakowitsch J., Winkler S., Dunkler D., Gerner C., Wagner O., Lang I.M., Kubicek M. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb. Haemost. 2009, 102:564-572.
26. Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., Bauernfeind F.G., Abela G.S., Franchi L., Nuñez G., Schnurr M., Espevik T., Lien E., Fitzgerald K.A., Rock K.L., Moore K.J., Wright S.D., Hornung V., Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
27. Edmunds L.H. Inflammatory response to cardiopulmonary bypass. Ann. Thorac. Surg. 1998, 66:S12-S16. (discussion S25-S28).
28. Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 2013, 13:34-45.
29. Engström G., Hedblad B., Janzon L., Lindgärde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur. J. Cardiovasc. Prev. Rehabil. 2007, 14:392-397.
30. Fairweather D., Frisancho-Kiss S., Njoku D.B., Nyland J.F., Kaya Z., Yusung S.A., Davis S.E., Frisancho J.A., Barrett M.A., Rose N.R. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J. Immunol. 2006, 176:3516-3524.
31. Ferreira V., Valck C., Sánchez G., Gingras A., Tzima S., Molina M.C., Sim R., Schwaeble W., Ferreira A. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J. Immunol. 2004, 172:3042-3050.
32. Frangogiannis N.G. The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J. Cardiovasc. Pharmacol. 2014, 63:185-195.
33. Frauenknecht V., Thiel S., Storm L., Meier N., Arnold M., Schmid J.P., Saner H., Schroeder V. Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin. Exp. Immunol. 2013, 173:112-120.
34. Gehrs K.M., Jackson J.R., Brown E.N., Allikmets R., Hageman G.S. Complement, age-related macular degeneration and a vision of the future. Arch. Ophthalmol. 2010, 128:349-358.
35. Gerczuk P.Z., Kloner R.A. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J. Am. Coll. Cardiol. 2012, 59:969-978.
36. Gombos T., Förhécz Z., Pozsonyi Z., Széplaki G., Kunde J., Füst G., Jánoskuti L., Karádi I., Prohászka Z. Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure. Clin. Res. Cardiol.: Off. J. Ger. Card. Soc. 2012, 101:607-615.
37. Gorsuch W.B., Chrysanthou E., Schwaeble W.J., Stahl G.L. The complement system in ischemia-reperfusion injuries. Immunobiology 2012, 217:1026-1033.
38. Granger C.B., Mahaffey K.W., Weaver W.D., Theroux P., Hochman J.S., Filloon T.G., Rollins S., Todaro T.G., Nicolau J.C., Ruzyllo W., Armstrong P.W. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003, 108:1184-1190. COMMA Investigators.
39. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 2011, 12:204-212.
40. Hansson G.K., Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 2006, 6:508-519.
41. Haskard D.O., Boyle J.J., Mason J.C. The role of complement in atherosclerosis. Curr. Opin. Lipidol. 2008, 19:478-482.
42. Haverich A., Shernan S.K., Levy J.H., Chen J.C., Carrier M., Taylor K.M., Van de Werf F., Newman M.F., Adams P.X., Todaro T.G., van der Laan M., Verrier E.D. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann. Thorac. Surg. 2006, 82:486-492.
43. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013, 381:166-175.
44. Hijazi Z., Oldgren J., Siegbahn A., Granger C.B., Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur. Heart J. 2013, 34:1475-1480.
45. Hill J.H., Ward P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J. Exp. Med. 1971, 133:885-900.
46. Hoffmeister H.M., Ehlers R., Büttcher E., Kazmaier S., Szabo S., Beyer M.E., Steinmetz A., Seipel L. Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris. Am. J. Cardiol. 2002, 89:909-912.
47. Holt C.B., Thiel S., Munk K., Ostergaard J.A., Bøtker H.E., Hansen T.K. Association between endogenous complement inhibitor and myocardial salvage in patients with myocardial infarction. Eur. Heart J. Acute Cardiovasc. Care 2014, 3:3-9.
48. Horváth Z., Csuka D., Vargova K., Kovács A., Molnár A.A., Gulácsi-Bárdos P., Leé S., Varga L., Kiss R.G., Préda I., Füst G. Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease. Mol. Immunol. 2012, 54:8-13.
49. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
50. Iyer A., Woodruff T.M., Wu M.C., Stylianou C., Reid R.C., Fairlie D.P., Taylor S.M., Brown L. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats. J. Cardiovasc. Pharmacol. 2011, 58:479-486.
51. Jennings R.B. Historical perspective on the pathology of myocardial ischemia/reperfusion injury. Circ. Res. 2013, 113:428-438.
52. Jordan J.E., Montalto M.C., Stahl G.L. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001, 104:1413-1418.
53. Kardys I., Klaver C.C., Despriet D.D., Bergen A.A., Uitterlinden A.G., Hofman A., Oostra B.A., Van Duijn C.M., de Jong P.T., Witteman J.C. A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam study. J. Am. Coll. Cardiol. 2006, 47:1568-1575.
54. Kishida K., Nakagawa Y., Kobayashi H., Mazaki T., Yokoi H., Yanagi K., Funahashi T., Shimomura I. High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome. Cardiovasc. Diabetol. 2014, 13:9.
55. Kloner R.A. Current state of clinical translation of cardioprotective agents for acute myocardial infarction. Circ. Res. 2013, 113:451-463.
56. Lappegård K.T., Bjørnstad H. Anti-inflammatory effect of cardiac resynchronization therapy. Pacing Clin. Electrophysiol. 2006, 29:753-758.
57. Lappegård K.T., Hovland A., Pop G.A., Mollnes T.E. Atrial fibrillation: inflammation in disguise?. Scand. J. Immunol. 2013, 78:112-119.
58. Lazar H.L., Bokesch P.M., van Lenta F., Fitzgerald C., Emmett C., Marsh H.C., Ryan U. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 2004, 110:II274-II279. OBE the TP10 Cardiac Surgery Study Group.
59. Lazar H.L., Keilani T., Fitzgerald C.A., Shapira O.M., Hunter C.T., Shemin R.J., Marsh H.C., Ryan U.S. Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference?. Circulation 2007, 116:I83-I88. TP10 Cardiac Surgery Study Group.
60. Leban N., Jraba K., Chalghoum A., Hassine S., Elhayek D., Denden S., Lakhdhar R., Maatoug F., Gamra H., Braham H., Chibani J.B., Khelil A.H. Polymorphism of C3 complement in association with myocardial infarction in a sample of central Tunisia. Diagn. Pathol. 2013, 8:93.
61. Lindberg S., Pedersen S.H., Mogelvang R., Galatius S., Flyvbjerg A., Jensen J.S., Bjerre M. Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Am. Heart J. 2012, 164:786-792.
62. Luz P.R., Boldt A.B., Grisbach C., Kun J.F., Velavan T.P., Messias-Reason I.J. Association of l-ficolin levels and FCN2 genotypes with chronic Chagas disease. PLOS ONE 2013, 8:e60237.
63. Mahaffey K.W., Granger C.B., Nicolau J.C., Ruzyllo W., Weaver W.D., Theroux P., Hochman J.S., Filloon T.G., Mojcik C.F., Todaro T.G., Armstrong P.W. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003, 108:1176-1183. COMPLY Investigators.
64. Maisel W.H., Rawn J.D., Stevenson W.G. Atrial fibrillation after cardiac surgery. Ann. Intern. Med. 2001, 135:1061-1073.
65. Martel C., Granger C.B., Ghitescu M., Stebbins A., Fortier A., Armstrong P.W., Bonnefoy A., Theroux P. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Am. Heart J. 2012, 164:43-51.
66. Mellbin L.G., Bjerre M., Thiel S., Hansen T.K. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care 2012, 35:911-917.
67. Mollnes T.E., Andreassen I.H., Høgåsen K., Hack C.E., Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol. Immunol. 1997, 34:719-729.
68. Mollnes T.E., Christiansen D., Brekke E.O.L., Espevik T. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv. Exp. Med. Biol. 2008, 632:253-263.
69. Moran A.E., Forouzanfar M.H., Roth G., Mensah G., Ezzati M., Murray C.J., Naghavi M. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980-2010: the global burden of disease 2010 study. Circulation 2014, 129:1483-1492.
70. Moran A.E., Forouzanfar M.H., Roth G., Mensah G.A., Ezzati M., Flaxman A., Murray C.J., Naghavi M. The global burden of ischemic heart disease in 1990 and 2010: the global burden of disease 2010 study. Circulation 2014, 129:1493-1501.
71. Mueller M., Herzog C., Larmann J., Schmitz M., Hilfiker-Kleiner D., Gessner J.E., Theilmeier G. The receptor for activated complement factor 5 (C5aR) conveys myocardial ischemic damage by mediating neutrophil transmigration. Immunobiology 2013, 218:1131-1138.
72. Mullick A., Tremblay J., Leon Z., Gros P. A novel role for the fifth component of complement (C5) in cardiac physiology. PLoS ONE 2011, 6:e22919.
73. Nicaud V., Francomme C., Ruidavets J.B., Luc G., Arveiler D., Kee F., Evans A., Morrison C., Blankenberg S., Cambien F., Tiret L. Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction. J. Mol. Med. 2007, 85:771-775.
74. Niederbichler A.D., Hoesel L.M., Westfall M.V., Gao H., Ipaktchi K.R., Sun L., Zetoune F.S., Su G.L., Arbabi S., Sarma J.V., Wang S.C., Hemmila M.R., Ward P.A. An essential role for complement C5a in the pathogenesis of septic cardiac dysfunction. J. Exp. Med. 2006, 203:53-61.
75. Nilsson B., Hamad O.A., Ahlström H., Kullberg J., Johansson L., Lindhagen L., Haenni A., Ekdahl K.N., Lind L. C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur. J. Clin. Investig. 2014, (Epub ahead of print 22.04.14).
76. Nunes M.C., Dones W., Morillo C.A., Encina J.J., Ribeiro A.L., Council on Chagas Disease of the Interamerican Society of Cardiology Chagas disease: an overview of clinical and epidemiological aspects. J. Am. Coll. Cardiol. 2013, 62:767-776.
77. Øhlenschlaeger T., Garred P., Madsen H.O., Jacobsen S. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. New Engl. J. Med. 2004, 351:260-267.
78. Oksjoki R., Laine P., Helske S., Vehmaan-Kreula P., Mäyränpää M.I., Gasque P., Kovanen P.T., Pentikäinen M.O. Receptors for the anaphylatoxins C3a and C5a are expressed in human atherosclerotic coronary plaques. Atherosclerosis 2007, 195:90-99.
79. Oliveira G.H., Brann C.N., Becker K., Thohan V., Koerner M.M., Loebe M., Noon G.P., Torre-Amione G. Dynamic expression of the membrane attack complex (MAC) of the complement system in failing human myocardium. Am. J. Cardiol. 2006, 97:1626-1629.
80. Ørn S., Manhenke C., Ueland T., Damås J.K., Mollnes T.E., Edvardsen T., Aukrust P., Dickstein K. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur. Heart J. 2009, 30:1180-1186.
81. Ovize M., Thibault H., Przyklenk K. Myocardial conditioning: opportunities for clinical translation. Circ. Res. 2013, 113:439-450.
82. Palikhe A., Sinisalo J., Seppänen M., Haario H., Meri S., Valtonen V., Nieminen M.S., Lokki M.L. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am. J. Cardiol. 2007, 99:890-895.
83. Prohászka Z., Munthe-Fog L., Ueland T., Gombos T., Yndestad A., Förhécz Z., Skjoedt M.O., Pozsonyi Z., Gustavsen A., Jánoskuti L., Karádi I., Gullestad L., Dahl C.P., Askevold E.T., Füst G., Aukrust P., Mollnes T.E., Garred P. Association of ficolin-3 with severity and outcome of chronic heart failure. PLOS ONE 2013, 8:e60976.
84. Ramírez G., Valck C., Molina M.C., Ribeiro C.H., López N., Sánchez G., Ferreira V.P., Billetta R., Aguilar L., Maldonado I., Cattán P., Schwaeble W., Ferreira A. Trypanosoma cruzi calreticulin: a novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity. Immunobiology 2011, 216:265-273.
85. Rassi A., Rassi A., Marin-Neto J.A. Chagas disease. Lancet 2010, 375:1388-1402.
86. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
87. Rubens F.D., Nathan H., Labow R., Williams K.S., Wozny D., Karsh J., Ruel M., Mesana T. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass. Ann. Thorac. Surg. 2005, 79:655-665.
88. Samstad E.O., Niyonzima N., Nymo S., Aune M.H., Ryan L., Bakke S.S., Lappegård K.T., Brekke O.L., Lambris J.D., Damås J.K., Latz E., Mollnes T.E., Espevik T. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 2014, 192:2837-2845.
89. Schoos M.M., Munthe-Fog L., Skjoedt M.O., Ripa R.S., Lønborg J., Kastrup J., Kelbæk H., Clemmensen P., Garred P. Association between lectin complement pathway initiators C-reactive protein and left ventricular remodeling in myocardial infarction - a magnetic resonance study. Mol. Immunol. 2013, 54:408-414.
90. Shandelya S.M., Kuppusamy P., Herskowitz A., Weisfeldt M.L., Zweier J.L. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation 1993, 88:2812-2826.
91. Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., Becker C.E., Ediriweera H.N., Mullick A.E., Golenbock D.T., Stuart L.M., Latz E., Fitzgerald K.A., Moore K.J. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat. Immunol. 2013, 14:812-820.
92. Shernan S.K., Fitch J.C., Nussmeier N.A., Chen J.C., Rollins S.A., Mojcik C.F., Malloy K.J., Todaro T.G., Filloon T., Boyce S.W., Gangahar D.M., Goldberg M., Saidman L.J., Mangano D.T. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann. Thorac. Surg. 2004, 77:942-950. Pexelizumab Study Investigators.
93. Siezenga M.A., Shaw P.K., Daha M.R., Rabelink T.J., Berger S.P. Low mannose-binding lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study. Cardiovasc. Diabetol. 2011, 10:60.
94. 2+/calmodulin-dependent kinase II triggers cell membrane injury by inducing complement factor B gene expression in the mouse heart. J. Clin. Investig. 2009, 119:986-996.
95. Singh M.V., Swaminathan P.D., Luczak E.D., Kutschke W., Weiss R.M., Anderson M.E. MyD88 mediated inflammatory signaling leads to CaMKII oxidation, cardiac hypertrophy and death after myocardial infarction. J. Mol. Cell. Cardiol. 2012, 52:1135-1144.
96. Smith P.K., Shernan S.K., Chen J.C., Carrier M., Verrier E.D., Adams P.X., Todaro T.G., Muhlbaier L.H., Levy J.H. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J. Thorac. Cardiovasc. Surg. 2011, 142:89-98. PRIMO-CABG II Investigators.
97. Sofat R., Casas J.P., Kumari M., Talmud P.J., Ireland H., Kivimaki M., Marmot M., Hughes A.D., Thom S., Ebrahim S., Whittaker J.C., Smeeth L., Lawlor D.A., Humphries S.E., Hingorani A.D. Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis 2010, 213:184-190.
98. Sosoniuk E., Vallejos G., Kenawy H., Gaboriaud C., Thielens N., Fujita T., Schwaeble W., Ferreira A., Valck C. Trypanosoma cruzi calreticulin inhibits the complement lectin pathway activation by direct interaction with l-ficolin. Mol. Immunol. 2014, 60:80-85.
99. Speidl W.S., Exner M., Amighi J., Kastl S.P., Zorn G., Maurer G., Wagner O., Huber K., Minar E., Wojta J., Schillinger M. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur. Heart J. 2005, 26:2294-2299.
100. Stark K., Neureuther K., Sedlacek K., Hengstenberg W., Fischer M., Baessler A., Wiedmann S., Jeron A., Holmer S., Erdmann J., Schunkert H., Hengstenberg C. The common Y402H variant in complement factor H gene is not associated with susceptibility to myocardial infarction and its related risk factors. Clin. Sci. 2007, 113:213-218.
101. Széplaki G., Prohászka Z., Duba J., Rugonfalvi-Kiss S., Karádi I., Kókai M., Kramer J., Füst G., Kleiber M., Romics L., Varga L. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 2004, 177:383-389.
102. Testa L., Van Gaal W.J., Bhindi R., Biondi-Zoccai G.G., Abbate A., Agostoni P., Porto I., Andreotti F., Crea F., Banning A.P. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg. 2008, 136:884-893.
103. Thomas T.C., Rollins S.A., Rother R.P., Giannoni M.A., Hartman S.L., Elliott E.A., Nye S.H., Matis L.A., Squinto S.P., Evans M.J. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 1996, 33:1389-1401.
104. Timmers L., Pasterkamp G., de Hoog V.C., Arslan F., Appelman Y., de Kleijn D.P. The innate immune response in reperfused myocardium. Cardiovasc. Res. 2012, 94:276-283.
105. Torzewski M., Bhakdi S. Complement and atherosclerosis-united to the point of no return?. Clin. Biochem. 2013, 46:20-25.
106. Trendelenburg M., Theroux P., Stebbins A., Granger C., Armstrong P., Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur. Heart J. 2010, 31:1181-1187.
107. Valck C., Ramírez G., López N., Ribeiro C.H., Maldonado I., Sánchez G., Ferreira V.P., Schwaeble W., Ferreira A. Molecular mechanisms involved in the inactivation of the first component of human complement by Trypanosoma cruzi calreticulin. Mol. Immunol. 2010, 47:1516-1521.
108. van der Pals J., Koul S., Andersson P., Götberg M., Ubachs J.F., Kanski M., Arheden H., Olivecrona G.K., Larsson B., Erlinge D. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovasc. Disord. 2010, 10:45.
109. Vengen I.T., Madsen H.O., Garred P., Platou C., Vatten L., Videm V. Mannose-binding lectin deficiency is associated with myocardial infarction: the HUNT2 study in Norway. PLoS ONE 2012, 7:e42113.
110. Verrier E.D., Shernan S.K., Taylor K.M., Van de Werf F., Newman M.F., Chen J.C., Carrier M., Haverich A., Malloy K.J., Adams P.X., Todaro T.G., Mojcik C.F., Rollins S.A., Levy J.H., PRIMO-CABG Investigators Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. J. Am. Med. Assoc. 2004, 291:2319-2327.
111. Walsh M.C., Bourcier T., Takahashi K., Shi L., Busche M.N., Rother R.P., Solomon S.D., Ezekowitz R.A., Stahl G.L. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J. Immunol. 2005, 175:541-546.
112. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat. Med. 2011, 17:1410-1422.
113. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990, 249:146-151.
114. Weitzel T., Zulantay I., Danquah I., Hamann L., Schumann R.R., Apt W., Mockenhaupt F.P. Mannose-binding lectin and Toll-like receptor polymorphisms and Chagas disease in Chile. Am. J. Tropic. Med. Hyg. 2012, 86:229-232.
115. Yndestad A., Damås J.K., Øie E., Ueland T., Gullestad L., Aukrust P. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 2007, 9:236-241.
116. Zee R.Y., Diehl K.A., Ridker P.M. Complement factor H Y402H gene polymorphism C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study. Atherosclerosis 2006, 187:332-335.
117. Zhang M., Hou Y.J., Cavusoglu E., Lee D.C., Steffensen R., Yang L., Bashari D., Villamil J., Moussa M., Fernaine G., Jensenius J.C., Marmur J.D., Ko W., Shevde K. MASP-2 activation is involved in ischemia-related necrotic myocardial injury in humans. Int. J. Cardiol. 2013, 166:499-504.
118. Zhang C., Li Y., Wang C., Wu Y., Cui W., Miwa T., Sato S., Li H., Song W.C., Du J. Complement 5a receptor mediates angiotensin II-induced cardiac inflammation and remodeling. Arterioscler. Thromb. Vasc. Biol. 2014, (Epub ahead of print 17 April).